The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

    Herbert Lepor, William O. Williford, Michael J. Barry, Michael K. Brawer, Christopher L. Dixon, Glenn J. Gormley, Clair M. Haakenson, Madeline Machi, Perinchery Narayan, Robert J. Padley
    Image of study
    TLDR Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
    The study aimed to determine the efficacy of terazosin, finasteride, or both in treating benign prostatic hyperplasia (BPH). The study involved 3,047 men with moderate-to-severe BPH who were randomly assigned to receive either terazosin, finasteride, a combination of both, or a placebo. The results showed that both terazosin and finasteride were effective in reducing symptoms of BPH, but the combination of both did not provide any additional benefit. Terazosin was found to be more effective in improving urinary flow, while finasteride was more effective in reducing prostate size. The study concluded that both terazosin and finasteride are effective treatments for BPH, but the choice of treatment should be based on individual patient characteristics.
    View this study on nejm.org →

    Cited in this study

    Related